Literature DB >> 19186072

Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.

Zaher K Otrock1, Hassan A Hatoum, Ahmad H Awada, Rim S Ishak, Ali I Shamseddine.   

Abstract

Tumor hypoxia is a common feature of many cancers. A master regulator of hypoxic response is the transcription factor hypoxia-inducible factor-1 (HIF-1). It functions as a master regulator of oxygen and undergoes conformational changes in response to varying oxygen concentrations. In this paper, we review what has been described about HIF-1: its structure, its regulation and target genes, its role in cancer, and its implication for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19186072     DOI: 10.1016/j.critrevonc.2009.01.001

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  26 in total

1.  Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in esophageal adenocarcinoma risk: a case-only study.

Authors:  Rihong Zhai; Yang Zhao; Geoffrey Liu; Monica Ter-Minassian; I-Chen Wu; Zhaoxi Wang; Li Su; Kofi Asomaning; Feng Chen; Matthew H Kulke; Xihong Lin; Rebecca S Heist; John C Wain; David C Christiani
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

Review 2.  Hypoxia--implications for pharmaceutical developments.

Authors:  Lucas Donovan; Scott M Welford; John Haaga; Joseph LaManna; Kingman P Strohl
Journal:  Sleep Breath       Date:  2010-07-14       Impact factor: 2.816

Review 3.  Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives.

Authors:  Bingxue Shang; Zhifei Cao; Quansheng Zhou
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

Review 4.  A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.

Authors:  Klaus Podar; Kenneth C Anderson
Journal:  Cell Cycle       Date:  2010-05-01       Impact factor: 4.534

Review 5.  Pharmacologic activation of p53 by small-molecule MDM2 antagonists.

Authors:  Hong Shen; Carl G Maki
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

6.  Angiogenesis in triple-negative adenoid cystic carcinomas of the breast.

Authors:  Semir Vranic; Snjezana Frkovic-Grazio; Nurija Bilalovic; Zoran Gatalica
Journal:  Virchows Arch       Date:  2011-09-04       Impact factor: 4.064

7.  Expression of nerve growth factor and hypoxia inducible factor-1α and its correlation with angiogenesis in non-small cell lung cancer.

Authors:  Qing-Li Lu; Jian Liu; Xiao-Li Zhu; Wen-Jia Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-06-18

8.  Increased accumulation of hypoxia-inducible factor-1α with reduced transcriptional activity mediates the antitumor effect of triptolide.

Authors:  Zhao-Li Zhou; Zhi-Guo Luo; Bing Yu; Yi Jiang; Yi Chen; Jian-Ming Feng; Mei Dai; Lin-Jiang Tong; Zheng Li; Yuan-Chao Li; Jian Ding; Ze-Hong Miao
Journal:  Mol Cancer       Date:  2010-10-11       Impact factor: 27.401

Review 9.  Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.

Authors:  Orit Jacobson; Xiaoyuan Chen
Journal:  Pharmacol Rev       Date:  2013-09-24       Impact factor: 25.468

10.  The role of hypoxia in 2-butoxyethanol-induced hemangiosarcoma.

Authors:  Daphna Laifenfeld; Annalyn Gilchrist; David Drubin; Milena Jorge; Sean F Eddy; Brian P Frushour; Bill Ladd; Leslie A Obert; Mark M Gosink; Jon C Cook; Kay Criswell; Christopher J Somps; Petra Koza-Taylor; Keith O Elliston; Michael P Lawton
Journal:  Toxicol Sci       Date:  2009-10-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.